Colorectal cancer (CRC) is one of the commonest cancers globally. A unique aspect of CRC
is its intimate association with the gut microbiota, which forms an essential part of the tumour …

Accumulating evidence demonstrates that the oral pathobiont Fusobacterium nucleatum is
involved in the progression of an increasing number of tumors types. Thus far, the …

Overweight and obesity are associated with increased risk of develo** metabolic
disorders such as diabetes and cardiovascular diseases. However, besides these metabolic …

Purpose: The gut microbiome is involved in antitumor immunotherapy and chemotherapy
responses; however, evidence-based research on the role of gut microbiome in predicting …

P53 mutation is an important cause of chemoresistance in colorectal cancer (CRC). The
investigation and identification of the downstream targets and underlying molecular …

Colorectal cancer (CRC) is one of the most prevalent and deadly malignancies that can be
influenced by Fusobacterium nucleatum (Fn), a bacterium that promotes tumor development …

The naturally evolved and intestinal pathogenic Fusobacterium nucleatum (Fn)-induced
drug resistance profoundly impaired the efficacy of chemotherapy against colorectal cancer …

Human colorectal cancers (CRCs) are readily colonized by colibactin-producing E. coli
(CoPEC). CoPEC induces DNA double-strand breaks, DNA mutations, genomic instability …

Fusobacterium nucleatum (Fn) has long been found to be related to colorectal cancer
(CRC), which could promote colorectal tumor progression and cause cancer resistance to …

Background Chemoresistance is a critical factor contributing to poor prognosis in clinical
patients with cancer undergoing postoperative adjuvant chemotherapy. The role of gut …